Introduction
Epstein-Barr virus (EBV) is a gamma herpesvirus that is highly prevalent in humans (Henle et al., 1969 (Henle et al., , 1979 . Most primary infections occur within the ®rst few years of life and are either asymptomatic or associated with a mild febrile illness (Henle et al., 1969; Lang et al., 1977) . When delayed until adolescence or adulthood, primary EBV infection can cause infectious mononucleosis (Henle et al., 1968) . Although the primary infection is controlled principally by an antiviral T-cell response, EBV persists for the lifetime of the individual by infecting and establishing a latent infection in memory B lymphocytes (Babcock et al., 1998; Nilsson et al., 1971; Rickinson et al., 1975 Rickinson et al., , 1980 Yao et al., 1989) . B lymphocytes latently infected with EBV have the potential to produce inde®nitely proliferating lymphocytes as evidenced by the outgrowth of EBV-transformed lymphoblastoid cell lines (LCLs) when peripheral blood B lymphocytes are cultured in vitro (Henle et al., 1967) . For most people, latent infection is innocuous due to constant immune surveillance of infected cells. In contrast, immune-compromised individuals may incur a lymphoproliferative disease due to the lack of a continued immune response to EBV (Hamilton-Dutoit et al., 1991 Ho et al., 1985; MacMahon et al., 1991;  reviewed in Rickinson and Kie, 1996) .
EBV is etiologically associated with several human malignancies grouped by ethnicity or geography such as nasopharyngeal carcinoma in southern Chinese, Burkitt's lymphoma in Africans, Hodgkin's disease in North Americans and Europeans, and gastric carcinomas in people from industrialized nations (Epstein et al., 1967; Henle and Henle, 1970; Niedobitek et al., 1991; Shibata and Weiss, 1992; Weiss et al., 1987) . In vitro, EBV infects and transforms resting primary human B lymphocytes into continuously proliferating LCLs (Pope et al., 1968 (Pope et al., , 1969 reviewed in Rickinson and Kie, 1996) . Recombinant EBV reverse genetic analyses in conjunction with in vitro B lymphocyte growth transformation assays have delineated the EBV genes necessary for transformation, while biochemical analyses have identi®ed cellular proteins that are involved in EBV-mediated transformation.
In LCLs, expression of the EBV viral genome is restricted to two non-polyadenylated RNAs (EBERs), a family of BamHI-A rightward transcripts (BARTs), six EBV encoded nuclear antigenic proteins, EBNA1, -2, -3A, -3B, -3C, and -LP and three latent infection membrane proteins, LMP1, -2A and -2B Heller et al., 1982; Hennessy et al., 1983; , 1985 Hennessy and Kie, 1985; Longnecker and Kie, 1990; Smith et al., 1993) . Recombinant EBV genetic analyses in conjunction with in vitro B lymphocyte transformation assays reveal that EBNA-1, EBNA-LP, EBNA-2, EBNA-3A, EBNA-3C, and LMP1 are required for the establishment of LCLs, whereas EBERs, BARTs, EBNA-3B and LMP2A and 2B are dispensable (Cohen et al., 1989; Hammerschmidt and Sugden, 1989; Kaye et al., 1993; Lee et al., 1999; Longnecker et al., 1993; Mannick et al., 1991; Robertson et al., 1994; Swaminathan et al., 1991; Tomkinson and Kie, 1992; Tomkinson et al., 1993) . In particular, LMP1 is a critical determinant of EBV-mediated transformation. Not only is LMP1 required for the outgrowth of LCLs in vitro, but it is also necessary for the continued proliferation of an established LCL (Kilger et al., 1998) . Furthermore, LMP1 can malignantly transform certain ®broblast cell lines (Baichwal and Sugden, 1988; Moorthy and Thorley-Lawson, 1993a; Wang et al., 1985) .
LMP1 is a constitutively activated receptor-like molecule that transmits transforming signals from the plasma membrane to activate transcription factor NFkB and alter cell growth. LMP1 is a 386 amino acid protein that consists of a short cytoplasmic N-terminal domain, six transmembrane domains, and a long cytoplasmic C-terminal domain (CTD) . The cytoplasmic N-terminal domain tethers the ®rst membrane-spanning domain to the cytoplasm, but no sequences within this domain are essential for EBV growth transformation (Izumi et al., 1994) . The six transmembrane domains cause LMP1 to spontaneously aggregate within the plasma membrane which enables two sites in the C-terminal cytoplasmic domain (CTD) to interact with cellular proteins and mediate signaling (Floettmann and Rowe, 1997; Gires et al., 1997; Hatzivassiliou et al., 1998; Liebowitz et al., 1986) . Recombinant viral genetic and biochemical analyses show that these two sites in the CTD of LMP1 are critical for growth transformation and activation of NF-kB (Huen et al., 1995; Kaye et al., 1995; Mitchell and Sugden, 1995) . The ®rst region spans residues 187 ± 231 and constitutively interacts with the tumor necrosis factor (TNF) receptor associated factors TRAF1, TRAF2, TRAF3 and TRAF5 (Brodeur et al., 1997; Devergne et al., 1996 Devergne et al., , 1998 Mosialos et al., 1995) . The second region of the CTD encompasses residues 352 ± 386 and this region continuously interacts with TNF receptor-associated death domain-containing protein (TRADD) and TNF receptor-interacting protein (RIP) (Eliopoulos et al., 1999a; Izumi et al., 1999; (Figure 1 ).
The residues between these two transformationspeci®c regions of the LMP1 CTD, i.e., amino acids 232 ± 351, have no known role in activation of NF-kB and their role in B lymphocyte transformation is likewise not clear. Within residues 232 ± 351 are multiple serine and threonine phosphorylation sites and several copies of an imperfectly repeated 11 amino acid sequence that mediates an association with the tyrosine kinase JAK3 (Gires et al., 1999; Mann and Thorley-Lawson, 1987) . Threonine phosphorylation of the LMP1 CTD is important for the phenotypic transformation of RAT1 ®broblasts, but its role in B lymphocyte growth transformation has not been determined (Moorthy and Thorley-Lawson, 1993b ). However, interaction of LMP1 with JAK3 is not required for EBV-mediated transformation since JAK3-de®cient B lymphocytes from severe combined immunode®ciency patients can be transformed by EBV (Izuhara et al., 1996; Macchi et al., 1995; Russell et al., 1995) .
LMP1 activates Rel/NF-kB through TNF-R associated signaling proteins
Recombinant virus genetic analyses of the C-terminal domain of LMP1 in conjunction with B lymphocyte transformation assays revealed that the TRAF interaction site and the TRADD/RIP interaction site are critical for ecient outgrowth of transformed B lymphocytes Kaye et al., 1993 Kaye et al., , 1995 . Based on those analyses, the TRAF interaction site is designated transformation eector site 1 (TES1), while the TRADD/RIP interaction site is designated TES2. TES1 and TES2 are coincident with CTAR1 and CTAR2 (C-terminal activation region) described as NF-kB activating domains (Huen et al., 1995; Mitchell and Sugden, 1995) . Activation of NF-kB by LMP1 molecules is usually tested by co-transfecting 293 human embryonic kidney cells with an LMP1 expression vector and an NF-kB reporter plasmid. In such experiments, wildtype LMP1 strongly activates the NF-kB reporter gene. An LMP1 TES1/CTAR1 protein, which has the N terminus, the six membrane-spanning domains, and the membrane proximal 45 amino acids of the CTD (i.e., the TES1/CTAR1 domain), activates the NF-kB reporter 25% as well as wild-type LMP1. Similarly, an LMP TES2/CTAR2 protein, which expresses the N terminus and membrane-spanning domains fused inframe with the terminal 35 amino acids of the CTD (i.e., the TES2/CTAR2 domain) activates the NF-kB reporter about 75% as well as wild-type LMP1 (Huen et al., 1995; Mitchell and Sugden, 1995) . Genetic and biochemical analyses indicate that LMP1-induced activation of NF-kB is due to the interaction of LMP1 with TRAFs and TRADD or RIP (Devergne et al., , 1998 Eliopoulos et al., 1996 Eliopoulos et al., , 1999a Izumi et al., , 1999 Sandberg et al., 1997) .
LMP1 association with TRAFs is mediated through a sequence within TES1/CTAR1. Furthermore, TRAF association couples LMP1 TES1/CTAR1 to activation of NF-kB. Biochemical analyses reveal that LMP1 residues 199 ± 214 are sucient for interaction with TRAF1, TRAF2 and TRAF3 . LMP1 amino acids 204 ± 208 consist of a PXQXT/S motif that is also found in the core of the TRAF binding sites in TNF-R family members CD30 and CD40. Alanine-scanning mutagenesis of this core motif in LMP1 showed that mutations at P204 or Q206 abolish TRAF1 and TRAF2 binding . Concordantly, LMP1 TES1/CTAR1 P204 or Q206 mutants are impaired in their ability to activate Figure 1 A schematic of LMP1. LMP1 TES1/CTAR1 interacts with TRAF1, TRAF2, TRAF3 and TRAF5. TRAF association is necessary for both TES1/CTAR1-mediated Rel/NF-kB activation and EBV-mediated B lymphocyte growth transformation. LMP1 TES1/CTAR1 is sucient to initiate transformation in the absence of TES2/CTAR2. TES2/CTAR2 is required for the ecient long-term outgrowth of EBV-transformed lymphoblastoid cell lines. TES2/CTAR2 interacts with TRADD and RIP and they interact with TRAFs. Loss of TRADD and RIP binding correlates with loss of LMP1 TES2/CTAR2 mediated activation of NF-kB and with severely impaired outgrowth of lymphoblastoid cell lines an NF-kB reporter gene in 293 cells . Furthermore, a TRAF2 mutant with a deletion of amino acids 2 ± 86 has a dominant-negative eect on TNF-R2-, CD40-and LMP1 TES1/CTAR1-mediated activation of NF-kB Rothe et al., 1995) . These results provide evidence that TRAFs are the cellular signal transducing proteins through which LMP1 TES1/CTAR1 activates NF-kB.
The PXQXT/S core motif in TES1/CTAR1 is the sole TRAF binding site in LMP1. An LMP1 mutant in which P204 and Q206 are changed to alanines does not co-immunoprecipitate any TRAF from BJAB Burkitt's lymphoma or cervical carcinoma cells (Devergne et al., 1998) . Likewise, an LMP1 CTD mutant in which T208 and D209 are converted to alanines fails to precipitate TRAF3 in binding assays (Brodeur et al., 1997) . Although there are other sequences in the LMP1 CTD with identity to the core TRAF binding motif, they do not function as TRAF interaction sites (Brodeur et al., 1997; Devergne et al., 1998; Franken et al., 1996) . LMP1 TES1/CTAR1 activates NF-kB about 25% as well as LMP1 when transiently expressed in 293 cells. The relative contribution of TES1/CTAR1 to NF-kB may be greater in an LCL because 293 cells do not express TRAF1. TRAF1 contributes to actvation of NF-kB by TES1/CTAR1 as TRAF1 expression in 293 cells synergizes with LMP1 TES1/CTAR1 to activate NF-kB to a level similar to that seen with LMP1 TES2/CTAR2 . Important residues within TES2/CTAR2 have been precisely delineated by mutational analyses. TES2/ CTAR2 was initially identi®ed as residues 352 ± 386; however, scanning mutation analyses revealed that amino acids 379 ± 384 are essential for NF-kB activation in B lymphoma cell lines (Floettmann and Rowe, 1997). In 293 cells, deletion of residues 374 ± 386 abolishes LMP1 TES2/CTAR2-mediated activation of NF-kB, and residues 376 ± 386 are sucient for NF-kB activation (Izumi et al., 1999) . These residues are highly conserved in the LMP1 proteins of the EBVrelated herpesviruses in baboons and rhesus monkeys (Floettmann and Rowe, 1997; Franken et al., 1996) .
Several lines of evidence indicate that TES2/CTAR2 principally activates NF-kB through the TNF receptorassociated death domain-containing protein TRADD. In LCLs, LMP1 and TRADD are stably associated with each other . Co-transfection of LMP1 and TRADD expressing vectors into 293 cells synergistically activates NF-kB . Mutation of amino acids Y384 and Y385 within TES2/CTAR2 to a single isoleucine (LMP1 mutant 1-383ID) cripples LMP1 interaction with TRADD in a yeast two-hybrid assay and in mammalian cells (Izumi et al., 1999; . LMP1 mutant 1-383ID cannot synergistically activate NF-kB with a TRADD expressing vector (Izumi et al., 1999; . Finally, TRADD activates NF-kB through aggregation of TRAF2. Concordantly, expression of a TRADD mutant deleted of the TRAF2 association domain (TRADD residues 123 ± 293) or a dominant-negative TRAF2 mutant partially inhibits LMP1 TES2/CTAR2 activation of NF-kB (Izumi et al., 1999; Kaye et al., 1996) .
In addition to TRADD, co-immunoprecipitation and yeast two-hybrid assays reveal LMP1 interacts with RIP (Izumi et al., 1999) . The RIP interaction, like the TRADD interaction, is severely crippled by mutating Y384 and Y385 to isoleucine indicating that both TRADD and RIP bind to common sequences in LMP1 TES2/CTAR2. (Izumi et al., 1999) . However, RIP association with TES2/CTAR2 is not equivalent to TRADD binding. Whereas TRADD interacts with TES2/CTAR2 residues 355 ± 386 in a yeast two-hybrid assay, RIP interaction is too weak to detect or absent (Izumi et al., 1999) . Furthermore, TRADD and LMP1 TES2/CTAR2 expression exhibit synergy in NF-kB reporter assays whereas RIP and LMP1 TES2/CTAR2 expression do not (Izumi et al., 1999) .
LMP1 signaling through TRADD and RIP is dierent from TNF-R1 signaling. RIP has never been shown to co-immunoprecipitate with TNF-R1 whereas it does with LMPI. RIP is required for TNF-R1-mediated activation of NF-kB, but it is not required for LMP1-mediated activation of NF-kB (Kelliher et al., 1998; Ting et al., 1996) . LMP1-mediated activation of NF-kB is identical in both RIP-expressing and RIPde®cient Jurkat cell lines (Izumi et al., 1999) . Furthermore, blocking NF-kB-induced gene expression sensitizes cells to TNFa-mediated apoptosis through TRADD. In constrast, neither LMP1 nor LMP1 TES2/CTAR2 transient expression induces apoptosis in 293 cells when NF-kB activity is blocked (Izumi et al., 1999) . Thus, LMP1 interacts with TRADD and RIP in a manner that activates NF-kB without promoting apoptosis.
LMP1 activates the IkBa kinase pathway to eect activation of NF-kB LMP1 activates a signaling cascade to induce IkBa degradation that is similar to that induced by TNFa (reviewed in Karin, 1999) . After TNFa binding, TNF receptor TNF-R1 recruits TRADD and through TRADD further recruits RIP and TRAFs. TNF-R2 recruits TRAFs directly. TRAFs activate a kinase cascade consisting of NF-kB inducing kinase (NIK) or a NIK-like kinase and the IkB kinase complex containing IKKa and IKKb. The activated IKK-a/b complex can phosphorylate IkBa on serines 32 and 36 signaling IkBa ubiquinization and proteasomemediated degradation (reviewed in Karin, 1999) . Consequently, NF-kB is released and translocates to the nucleus where it binds to its cognate sequences within the promoter/regulatory regions of many genes. The TES1/CTAR1 and TES2/CTAR2 domains of LMP1 activate NF-kB along the same pathway since overexpression of dominant-negative mutants of TRAF2, NIK, IKKa and IKKb can each inhibit LMP1-induced activation of NF-kB Kaye et al., 1996; Sylla et al., 1998) .
Mutations of the TRAF-binding domain TES1/CTAR1 or the TRADD-and RIP-binding domain TES2/CTAR2 cripple EBV-mediated growth transformation of B lymphocytes
Mutations within the TES1/CTAR1 or TES2/CTAR2 domains of LMP1 reduce its ability to activate NF-kB. Moreover, EBV recombinants, constructed with the same mutations, are defective in B lymphocyte transformation assays. These results link EBV-mediated growth transformation to activation of NFkB. Deletion of amino acids 185 ± 211 of LMP1 removes the TRAF binding core within TES1/ CTAR1 and abolishes TES1/CTAR1-mediated activation of NF-kB, but does not aect TES2/CTAR2-mediated NF-kB activation through TRADD. EBV recombinants harboring this TES1/CTAR1 deletion are unable to growth transform B lymphocytes. Thus, TES1/CTAR1-mediated activation of NF-kB is critical for EBV-mediated transformation. Similarly, deletion of the TRADD and RIP binding site cripples EBVmediated growth transformation. EBV recombinants that express only the N terminus, the six transmembrane domains and TES1/CTAR1 (residues 1 ± 231, called mutant MS231) are competent for initial growth transformation (Kaye et al., 1995) . However, most MS231-expressing LCLs fail to achieve long-term outgrowth unless complemented by co-cultivation with a ®broblast monolayer (Kaye et al., 1995) . These results indicate that TRAF binding and signaling is sucient for initial growth transformation, but that sequences beyond TES1/CTAR1 enable ecient LCL outgrowth. Therefore, TRADD and RIP binding to TES2/CTAR2 of LMP1 is implicated as enabling ecient long-term outgrowth, which is also supported by the ®nding that EBV recombinants expressing the LMP1 1-383ID mutation are crippled in B lymphocyte transformation assays .
Although these data genetically link NF-kB activation by LMP1 to growth transformation, they also clearly indicate that NF-kB activation is not sucient for transformation. That is, both NF-kB activating regions of LMP1 are required for ecient transformation of resting B lymphocytes to an LCL. Hence, TES1/CTAR1 and TES2/CTAR2 must each have unique properties that are essential to B lymphocyte growth transformation. Consistent with this hypothesis, LMP1 TES1/CTAR1 but not TES2/CTAR2 induces expression of TRAF1, the IL-12 homolog EBI3 and epidermal growth factor receptor in cell lines of dierent lineages (Devergne et al., 1998; Miller et al., 1997) . LMP1 TES1/CTAR1 and TES2/CTAR2 may activate dierent members of the Rel/NF-kB family or they may activate additional, and distinct, signaling pathways. For example, stress-activated protein kinases are dierentially activated by LMP1. Both LMP1 TES1/CTAR1 and LMP1 TES2/CTAR2 activate p38 whereas only LMP1 TES2/CTAR2 has been reported to activate JNK (Eliopoulos et al., 1999a,b; Eliopoulos and Young, 1998; Kieser et al., 1997) . The role of stress-activated kinases and their contribution to EBV-mediated growth transformation is not yet understood.
LMP1 protects cells from apoptosis
LMP1 protects cells from apoptosis in a number of model systems. In vitro, B-cell receptor (BCR) and CD40 engagement induces resting B lymphocytes to proliferate whereas BCR stimulation alone induces apoptosis (Banchereau et al., 1991; Liu et al., 1989) . LMP1 expression can substitute for CD40 engagement and protect WEHI 231 from BCR-mediated apoptosis (Busch and Bishop, 1999) . In an LCL established with an EBV recombinant in which EBNA2 and LMP1 expression can be silenced, both are required for continuous proliferation and protection from apoptosis. Importantly, LMP1 expression in trans or CD40 engagement can prolong cell survival in these cells (Zimber-Strobl et al., 1996) . LMP1 can also protect cells from serum starvation-, etoposide-, and p53-induced apoptosis (Fries et al., 1996; Kawanishi, 1997; Kenney et al., 1998) .
Rel/NF-kB family members play an essential role in protecting a variety of cells, including EBV-positive Hodgkin's lymphoma cells, from TNFa-mediated apoptosis (Asso-Bonnet et al., 1998; reviewed in Barkett and Gilmore, 1999) . Not surprisingly, activation of NF-kB by LMP1 is linked to its ability to prevent apoptosis. LMP1 expression in B lymphomas increases the expression of anti-apoptotic proteins Bcl-2, Mcl-1, A20 and TRAF1 Finke et al., 1992; Henderson et al., 1991; Kenney et al., 1998) . The genes for A20 and TRAF1 are NF-kB target genes and LMP1-mediated induction of both proteins is dependent on activation of NF-kB (Devergne et al., 1998; Laherty et al., 1992; Wang et al., 1998) . Thus, LMP1 aggregates TRAFs, TRADD and RIP, activates NF-kB, and protects cells from apoptosis.
Discussion
EBV, like HTLV-1 (Sun and Ballard, 1999, this issue) , has incorporated activation of NF-kB into the signaling program required for the transformation of human B lymphocytes. The EBV oncoprotein LMP1 is a constitutively activated receptor-like molecule that activates NF-kB by appropriating the cytoplasmic signaling proteins of tumor necrosis factor receptors. Namely, LMP1 interacts with adaptor proteins TRAF1, TRAF2, TRAF3 and TRAF5 through its TES1/CTAR1 and with TRADD and RIP through TES2/CTAR2. Genetic and biochemical analyses of recombinant EBV vectors link NF-kB activation to B lymphocyte growth transformation. Mutation of either protein interaction domain diminishes NF-kB activation by LMP1 and cripples either initial establishment of or outgrowth of lymphoblastoid cell lines. Thus, TRAF binding to TES1/CTAR1 and TRADD and RIP binding to TES2/CTAR2 aect cell growth in ways that are not interchangeable despite their common use of TRAFs, NIK, and the IkB kinase complex (including IKKa and IKKb). Additional studies will be aimed at delineating the unique signaling properties of TES1/CTAR1 and TES2/ CTAR2, and how they contribute to the transformation of human B lymphocytes by EBV.
